The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Rovaldi Christopher since 2017.
This trader's CIK number is 1706040.
At the time of last reporting, Rovaldi Christopher was the Chief Operating Officer of Keros Therapeutics, Inc.. (stock ticker symbol KROS).
Also see all insider trading activities at Keros Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | KROS | 0 | $0 | 2,592 | $161,434 | 2,592 | $41,472 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | XLRN | 0 | $0 | 16,766 | $726,390 | 11,000 | $265,210 |
| 2017 | XLRN | 0 | $0 | 14,000 | $548,702 | 0 | $0 |
1. Keros Therapeutics, Inc. (KROS)
2. Acceleron Pharma Inc (XLRN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-04-06 | KROS | Option Ex | 1,728 | 16.00 | 27,648 |
| 2022-04-06 | KROS | Sale | 1,728 | 65.00 | 112,320 |
| 2022-04-01 | KROS | Option Ex | 864 | 16.00 | 13,824 |
| 2022-04-01 | KROS | Sale | 864 | 56.85 | 49,114 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-04-03 | XLRN | Sale | 3,500 | 38.65 | 135,257 |
| 2018-01-12 | XLRN | Option Ex | 11,000 | 24.11 | 265,210 |
| 2018-01-12 | XLRN | Sale | 11,000 | 45.00 | 495,000 |
| 2018-01-02 | XLRN | Sale | 1,433 | 42.41 | 60,773 |
| 2018-01-03 | XLRN | Sale | 833 | 42.45 | 35,360 |
| 2017-09-12 | XLRN | Sale | 14,000 | 39.19 | 548,702 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Rovaldi Christopher (Chief Operating Officer of Keros Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.